Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531607 · ClinicalTrials.gov registry record
Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)
A clinical trial of Pancreatic Neoplasms, sponsored by AdventHealth.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT02531607: Active study of Pancreatic Neoplasms, sponsored by AdventHealth.
NCT02531607 is a study of Pancreatic Neoplasms that is active but no longer recruiting, run by AdventHealth. The registered enrollment target is 500 participants, below the 585-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02531607, a study of Pancreatic Neoplasms, is active but no longer recruiting, sponsored by AdventHealth.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized natural history protocol in which patients undergoing surgery or endoscopy for suspected/ diagnosed pancreaticobiliary strictures are assigned to a) control (chronic pancreatitis, no pancreatic neoplasm, primary sclerosing cholangitis), b) non-carcinoma (bile duct stones, papillary stenosis, ), c) carcinoma non-pancreatic (ampullary and distal bile duct or cholangiocarcinoma) and d) pancreatic ductal adenocarcinoma (pancreatic cancer.
Primary Outcome
Comparative efficacy of biomarkers, brush cytology, fluorescence in situ hybridization (FISH), carbohydrate antigen 19-9 (CA 19-9) and biliary and blood biomarkers (lipidomics, proteomics, micro RNAs and VOCs) in the diagnosis of malignancy.
Conditions Studied
Interventions
- OTHER blood and bile
Study Locations (1)
Florida
- AdventHealth - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2014-11-13 |
| Est. Completion | 2026-12-01 |
What the registry record for NCT02531607 still lists
NCT02531607 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which blood and bile is the first listed.
NCT02531607 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02531607 about?
NCT02531607 is a clinical study titled "Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)". This is a non-randomized natural history protocol in which patients undergoing surgery or endoscopy for suspected/ diagnosed pancreaticobiliary strictures are assigned to a) control (chronic pancreatitis, no pancreatic neoplasm, primary sclerosing cholangitis), b) non-carcinoma (bile duct stones, pa...
What is the current status of trial NCT02531607?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2014-11-13. Estimated completion is 2026-12-01.
What conditions does trial NCT02531607 study?
This clinical trial studies the following conditions: Pancreatic Neoplasms.
What interventions are being tested in trial NCT02531607?
The interventions under investigation include: blood and bile (OTHER).
Who is sponsoring clinical trial NCT02531607?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02531607 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02531607's enrollment target sits among peer trials
500 10th of 30 higher than 21 of 30 other Pancreatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
RECRUITING
-
Determining Individualized Cancer Therapy in Pancreatic Cancer
RECRUITING
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RECRUITING
-
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
RECRUITING
-
UCSF PANC Cyst Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI